Skip to main content
Top
Published in: Clinical and Translational Oncology 11/2017

01-11-2017 | Research Article

MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor

Authors: J. Wang, L. Li, M. Jiang, Y. Li

Published in: Clinical and Translational Oncology | Issue 11/2017

Login to get access

Abstract

Purpose

Gastric cancer (GC) is one of the fatal malignancies worldwide with high occurrences but poor outcomes. bFGF has been shown to play significant roles in GC. Yet, whether bFGF affects the development of GC is less studied.

Methods

MicroRNA assays, real-time PCR, and western blot were conducted for expression analysis of miR-195-5p and basic fibroblast growth factor (bFGF). Luciferase activity was measured with mutated bFGF 3′-UTR sequence at the 3′ end of the luciferase gene. Two GC cell lines, SNU-1 and KATO-3 overexpressing miR-195-5p and bFGF were subjected to wound healing assay and transwell invasion assay. Mouse GC xenograft model was established and subjected to tumor size analysis.

Results

Expression levels of miR-195-5p and bFGF showed negative correlation in human GC tissues. MiR-195-5p directly targeted bFGF 3′-UTR as demonstrated by luciferase activity assay. MiR-195-5p, through downregulating bFGF, inhibited the migration and invasion of SNU-1 and KATO-3 cells, as well as tumorigenesis in a xenograft mouse model, which could be restored by re-introduction of bFGF.

Conclusions

MiR-195-5p inhibits tumorigenesis of GC through suppressing bFGF, which supports both miR-195-5p and bFGF as potential therapeutic targets in the treatment of GC.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
go back to reference Power DG, Kelsen DP, Shah MA. Advanced gastric cancer—slow but steady progress. Cancer Treat Rev. 2010;36:384–92.CrossRefPubMed Power DG, Kelsen DP, Shah MA. Advanced gastric cancer—slow but steady progress. Cancer Treat Rev. 2010;36:384–92.CrossRefPubMed
3.
go back to reference Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMed Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMed
4.
go back to reference Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.CrossRefPubMed Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.CrossRefPubMed
5.
go back to reference Hong L, Han Y, Liu J, Brain L. Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer. Expert Rev Gastroenterol Hepatol. 2013;7:759–65.CrossRefPubMed Hong L, Han Y, Liu J, Brain L. Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer. Expert Rev Gastroenterol Hepatol. 2013;7:759–65.CrossRefPubMed
6.
go back to reference Okamoto W, Okamoto I, Arao T, et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012;11:1557–64.CrossRefPubMed Okamoto W, Okamoto I, Arao T, et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012;11:1557–64.CrossRefPubMed
7.
go back to reference Teng L, Lu J. cMET as a potential therapeutic target in gastric cancer (Review). Int J Mol Med. 2013;32:1247–54.CrossRefPubMed Teng L, Lu J. cMET as a potential therapeutic target in gastric cancer (Review). Int J Mol Med. 2013;32:1247–54.CrossRefPubMed
8.
go back to reference Bilgic I, Ozalp N, Tez M, Koc M. Serum bFGF concentrations in gastric cancer patients. Bratisl Lek Listy. 2008;109:8–9.PubMed Bilgic I, Ozalp N, Tez M, Koc M. Serum bFGF concentrations in gastric cancer patients. Bratisl Lek Listy. 2008;109:8–9.PubMed
9.
go back to reference Zhao ZS, Zhou JL, Yao GY, et al. Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J Gastroenterol. 2005;11:3227–33.CrossRefPubMedPubMedCentral Zhao ZS, Zhou JL, Yao GY, et al. Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J Gastroenterol. 2005;11:3227–33.CrossRefPubMedPubMedCentral
10.
go back to reference Brenner M, Degitz K, Besch R, Berking C. Differential expression of melanoma-associated growth factors in keratinocytes and fibroblasts by ultraviolet A and ultraviolet B radiation. Br J Dermatol. 2005;153:733–9.CrossRefPubMed Brenner M, Degitz K, Besch R, Berking C. Differential expression of melanoma-associated growth factors in keratinocytes and fibroblasts by ultraviolet A and ultraviolet B radiation. Br J Dermatol. 2005;153:733–9.CrossRefPubMed
11.
go back to reference Kim HS. Assignment1 of the human basic fibroblast growth factor gene FGF2 to chromosome 4 band q26 by radiation hybrid mapping. Cytogenet Cell Genet. 1998;83:73.CrossRefPubMed Kim HS. Assignment1 of the human basic fibroblast growth factor gene FGF2 to chromosome 4 band q26 by radiation hybrid mapping. Cytogenet Cell Genet. 1998;83:73.CrossRefPubMed
13.
go back to reference Sun D, Liu Y, Yu Q, et al. The effects of luminescent ruthenium(II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling. Biomaterials. 2013;34:171–80.CrossRefPubMed Sun D, Liu Y, Yu Q, et al. The effects of luminescent ruthenium(II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling. Biomaterials. 2013;34:171–80.CrossRefPubMed
14.
15.
go back to reference Hausser J, Zavolan M. Identification and consequences of miRNA-target interactions—beyond repression of gene expression. Nat Rev Genet. 2014;15:599–612.CrossRefPubMed Hausser J, Zavolan M. Identification and consequences of miRNA-target interactions—beyond repression of gene expression. Nat Rev Genet. 2014;15:599–612.CrossRefPubMed
16.
go back to reference Kohlhapp FJ, Mitra AK, Lengyel E, Peter ME. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 2015;34:5857–68.CrossRefPubMedPubMedCentral Kohlhapp FJ, Mitra AK, Lengyel E, Peter ME. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 2015;34:5857–68.CrossRefPubMedPubMedCentral
18.
19.
go back to reference Shen YH, Xie ZB, Yue AM, et al. Expression level of microRNA-195 in the serum of patients with gastric cancer and its relationship with the clinicopathological staging of the cancer. Eur Rev Med Pharmacol Sci. 2016;20:1283–7.PubMed Shen YH, Xie ZB, Yue AM, et al. Expression level of microRNA-195 in the serum of patients with gastric cancer and its relationship with the clinicopathological staging of the cancer. Eur Rev Med Pharmacol Sci. 2016;20:1283–7.PubMed
20.
go back to reference Gou WF, Yang XF, Shen DF, et al. The roles of BTG3 expression in gastric cancer: a potential marker for carcinogenesis and a target molecule for gene therapy. Oncotarget. 2015;6:19841–67.CrossRefPubMedPubMedCentral Gou WF, Yang XF, Shen DF, et al. The roles of BTG3 expression in gastric cancer: a potential marker for carcinogenesis and a target molecule for gene therapy. Oncotarget. 2015;6:19841–67.CrossRefPubMedPubMedCentral
22.
go back to reference Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.CrossRefPubMed Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.CrossRefPubMed
23.
go back to reference Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des. 2013;19:1292–300.CrossRefPubMed Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des. 2013;19:1292–300.CrossRefPubMed
24.
go back to reference Gorur A, Balci Fidanci S, Dogruer Unal N, et al. Determination of plasma microRNA for early detection of gastric cancer. Mol Biol Rep. 2013;40:2091–6.CrossRefPubMed Gorur A, Balci Fidanci S, Dogruer Unal N, et al. Determination of plasma microRNA for early detection of gastric cancer. Mol Biol Rep. 2013;40:2091–6.CrossRefPubMed
25.
26.
go back to reference Coleman SJ, Chioni AM, Ghallab M, et al. Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. EMBO Mol Med. 2014;6:467–81.CrossRefPubMedPubMedCentral Coleman SJ, Chioni AM, Ghallab M, et al. Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. EMBO Mol Med. 2014;6:467–81.CrossRefPubMedPubMedCentral
27.
go back to reference Khurana A, Liu P, Mellone P, et al. HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res. 2011;71:2152–61.CrossRefPubMedPubMedCentral Khurana A, Liu P, Mellone P, et al. HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res. 2011;71:2152–61.CrossRefPubMedPubMedCentral
28.
go back to reference Wang XH, Long ZW. Correlations of EGF G1380A, bFGF C754G and VEGF T460C polymorphisms with malignant melanoma susceptibility and prognosis: a case-control study. Gene. 2017;617:44–53.CrossRefPubMed Wang XH, Long ZW. Correlations of EGF G1380A, bFGF C754G and VEGF T460C polymorphisms with malignant melanoma susceptibility and prognosis: a case-control study. Gene. 2017;617:44–53.CrossRefPubMed
Metadata
Title
MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor
Authors
J. Wang
L. Li
M. Jiang
Y. Li
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 11/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1668-4

Other articles of this Issue 11/2017

Clinical and Translational Oncology 11/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine